Evidence map›Paper›PMID 40264059›Full record

ArticleBMC public health2025

Integrating routine immunization into COVID-19 vaccination improve coverage but could create equity issues: evidence from Niger State, Nigeria.

Hilary I Okagbue, Akolade Jimoh, Olugbemisola Samuel, Hadley Ikwe, Saheed Isiaka, Irene Okoye, Joshua David, Zubair Adegoke

Abstract read
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hilary I OkagbueSydani Institute for Research and Innovation, Sydani Group, Abuja, Nigeria. tobyhilly@yahoo.com.
Akolade JimohSydani Group, Abuja, Nigeria.
Olugbemisola SamuelSydani Institute for Research and Innovation, Sydani Group, Abuja, Nigeria.
Hadley IkweGlobal Immunization Division, United States, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Saheed IsiakaSydani Institute for Research and Innovation, Sydani Group, Abuja, Nigeria.
Irene OkoyeSydani Group, Abuja, Nigeria.
Joshua DavidSydani Group, Abuja, Nigeria.
Zubair AdegokeSydani Group, Abuja, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntegrating Routine Immunization (RI) into COVID-19 vaccination implies that COVID-19 vaccination is the primary focus, with RI services added to the effort. During COVID-19 vaccination campaigns in Nigeria, healthcare workers also provided routine vaccines such as measles and polio to individuals who came for their COVID-19 shots. This paper aims to demonstrate that integrating RI into COVID-19 vaccination increases overall vaccine coverage but may introduce equity issues. METHODOLOGY: The data used in this study consist of COVID-19 immunization records (first, second, and booster doses) from 23 local government areas (LGAs) in Niger State, Nigeria. The project aimed to vaccinate the remaining 30% of the population who had not received any COVID-19 vaccine doses. Two LGAs were excluded due to security concerns. Routine immunizations (RIs) provided alongside COVID-19 vaccinations included the inactivated polio vaccine (IPV), oral polio vaccine (OPV), pentavalent polio vaccine (PENTA), and other vaccines based on specific needs, primarily targeting zero-dose children. The primary outcome was vaccine coverage, measured as the percentage of targeted individuals who received at least one dose of the COVID-19 vaccine. Secondary outcomes included the uptake of routine immunization during COVID-19 vaccination campaigns and a gender equity analysis to assess disparities in vaccination rates between males and females.

resultsA total of 436,598 individuals were vaccinated, with a daily average of 3,898. Among those vaccinated, 49.78% were male, while 50.22% were female, achieving a percentage coverage of 101%. Of the vaccinated individuals, 76% received a single dose, 5.1% received a second dose, and 18.3% received a booster dose. Among those who received a single dose, 49.9% were male and 50.1% were female. Among those who received the second dose, 47.4% were male and 52.6% were female. Among those who received the booster dose, 49.8% were male and 50.2% were female. No significant mean differences were found between males and females for those who received the first and booster doses. Similarly, there were no significant mean differences between the targeted and achieved vaccinations, despite variations in coverage across the 23 LGAs. Additionally, 60,373 routine immunizations were administered alongside COVID-19 vaccinations. A breakdown of the RI distribution showed that 17.6% of recipients received PENTA, 18.3% received OPV, 17.6% received IPV, and 46.5% received other vaccines. A significant mean difference was observed between males and females when RI was integrated into COVID-19 vaccinations, suggesting a gender disparity.

conclusionAlthough integrating RI into COVID-19 vaccination efforts increased overall immunization coverage, the data suggest potential inequities, as a higher proportion of RI doses were administered to females. This finding highlights differences in vaccine access between males and females. Further research is needed to understand the impact of gender differences in RI integration and to promote equitable vaccination access for all.

Indexed as

COVID-19COVID-19 VaccinesHealth EquityImmunization ProgramsVaccination CoverageAdolescentAdultChildChild, PreschoolFemaleHumansInfantMaleMiddle AgedNigerNigeriaCOVID-19 VaccinesCOVID-19 vaccinationEquityGenderIntegrationRoutine immunization, vaccine

Identifiers

PMID40264059
PMCPMC12013195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.